The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway

Background/Aims: Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve better glucose control in patients with type 2 diabetes, and GLP-1 mimetics such as liraglutide have shown therapeutic potential in preventing diabetes-related microvascular and macrovascular complications as well...

Full description

Bibliographic Details
Main Authors:	Yi Bao, Lei Jiang, Haiyan Chen, Junjie Zou, Zhimin Liu, Yongquan Shi
Format:	Article
Language:	English
Published:	Cell Physiol Biochem Press GmbH & Co KG 2015-07-01
Series:	Cellular Physiology and Biochemistry
Subjects:	Liraglutide AGEs Astrocytes cAMP GLP-1
Online Access:	http://www.karger.com/Article/FullText/430199

Similar Items

Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway
by: Li Wang, et al.
Published: (2019-10-01)

The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
by: Qihong Que, et al.
Published: (2019-06-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

Glucagon-like peptide-1 analogue, liraglutide, delays onset and reduces severity of experimental autoimmune encephalitis in Lewis rats
by: Brian DellaValle, et al.
Published: (2016-11-01)

Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R
by: Ziyi Li, et al.
Published: (2020-10-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats
by: Kai-Chun Cheng, et al.
Published: (2020-11-01)

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
by: Mala Dharmalingam, et al.
Published: (2011-01-01)

Complex vasoactivity of liraglutide. Contribution of three gasotransmitters
by: Eszter Sélley, et al.
Published: (2015-05-01)

Gap Junction-Mediated Intercellular Communication of cAMP Prevents CDDP-Induced Ototoxicity via cAMP/PKA/CREB Pathway
by: Yeon Ju Kim, et al.
Published: (2021-06-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Effects of liraglutide on obesity-associated functional hypogonadism in men
by: M Jensterle, et al.
Published: (2019-02-01)

Glucagon-like peptide-1 (GLP-1) and liraglutide, a synthetic GLP-1 analog, inhibit inflammation in human aortic endothelial cells via calcium and AMPK dependent mechanisms
by: Krasner, Nadia Marie
Published: (2016)

LIRAGLUTIDE: SUCESSO NO TRATAMENTO DO DIABETES MELLITUS EM MONOTERAPIA E ASSOCIAÇÕES – REVISÃO SISTEMÁTICA
by: George Robson Ibiapina, et al.
Published: (2011-12-01)

Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
by: Natia Peradze, et al.
Published: (2019-10-01)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
by: Xu Zhao, et al.
Published: (2019-01-01)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
by: Åke Sjöholm
Published: (2010-03-01)

Rottlerin Reduces cAMP/CREB-Mediated Melanogenesis via Regulation of Autophagy
by: Nurinanda Prisky Qomaladewi, et al.
Published: (2019-04-01)

Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer
by: Wang S, et al.
Published: (2018-07-01)

Enhancement of Astroglial Aerobic Glycolysis by Extracellular Lactate-Mediated Increase in cAMP
by: Nina Vardjan, et al.
Published: (2018-05-01)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
by: Mariana Cornelia Tilinca, et al.
Published: (2021-06-01)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
by: Louise Vedtofte, et al.
Published: (2020-10-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure
by: Abhinav Sharma, et al.
Published: (2021-08-01)

Liraglutids viktminskningseffekt
by: Hazime, Zahraa
Published: (2020)

Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism
by: Mei-Yueh Lee, et al.
Published: (2019-09-01)

The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study
by: Christina Bording Rasmussen, et al.
Published: (2014-08-01)

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
by: Vaia Lambadiari, et al.
Published: (2018-01-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Calcium-independent phospholipase A2 mediates CREB phosphorylation in double-stranded RNA-stimulated endothelial cells
by: Bradley D. Martinson, et al.
Published: (2003-09-01)

Liraglutide overdose: A case report and an updated review
by: Sharafaldeen Bin Nafisah, et al.
Published: (2020-01-01)

Endogenous Parathyroid Hormone Promotes Fracture Healing by Increasing Expression of BMPR2 through cAMP/PKA/CREB Pathway in Mice
by: Wei Zhou, et al.
Published: (2017-06-01)

Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
by: Wei Xie, et al.
Published: (2018-05-01)

The Astrocytic cAMP Pathway in Health and Disease
by: Zhiwen Zhou, et al.
Published: (2019-02-01)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
by: Li Z, et al.
Published: (2019-09-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

cAMP/PKA/CREB/GLT1 signaling involved in the antidepressant-like effects of phosphodiesterase 4D inhibitor (GEBR-7b) in rats
by: Liu X, et al.
Published: (2016-01-01)